Posted 17th July 2017 by Jane Williams
In recent times, we have seen advances in precision medicine lead to powerful discoveries and improved patient care. Liquid biopsies for example, now have the potential to be a real game-changer in cancer testing and could revolutionise cancer care.
Posted 12th July 2017 by Jane Williams
With so many promising cancer therapies emerging from research labs, a key challenge for biomedical researchers is to develop tools that accurately predict treatment efficacy against a patient’s specific cancer, thereby avoiding subjecting the patient to a trial and error process to find the best drug.
Posted 7th June 2017 by Jane Williams
Unreasonable cost of trial-and-error medicine means precision medicine is imperative for targeted therapies
Rising pressures to decrease healthcare cost globally, the emergence of value-based reimbursement models and healthcare digitisation trends are transitioning the medication model from ‘one-size-fits-all’ to stratified and outcome based targeted therapies.
Posted 8th May 2017 by Jane Williams
Future of immunotherapies
Immunotherapies are on the fast growth trajectory which will be moderated based on responder groups, toxicity and efficacy results and high costs and increasingly used in combination therapies. The overall immune oncology checkpoint inhibitor market was over $2.0 billion and is set to grow to $14 billion by 2018.
Posted 20th February 2017 by Jane Williams
Jim Huggett’s research focuses on molecular diagnostics, genomics and nucleic acids, including cancer and foetal genetic analysis and the diagnosis of infectious diseases. We interviewed him about the latest developments and the latest advances in qPCR research.
Posted 17th February 2017 by Jane Williams
President Jimmy Carter announced last spring that he no longer needed treatments for the metastatic melanoma found in his brain – after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer.
Posted 11th November 2016 by Jane Williams
The genomic and post-genomic age promises much for clinical medicine, largely because we can now comprehensively sequence genomic DNA to identify polymorphisms, patterns and mutations. We can also measure gene expression routinely and systematically and with high sensitivity measure the amounts of proteins produced.
Posted 30th September 2016 by Jane Williams
The digitization of tissue glass slides is clearly opening up exciting opportunities as well as challenges to the world of computational imaging scientists. It is clear that while computational imaging can clearly play a role in better quantitative characterization of disease and precision medicine, there still remain a number of substantial technical and computational challenges that need to be overcome before computer assisted image analysis of digital pathology can become part of the routine clinical diagnostic workflow.